Elena E. Pavleeva

Elena E. Pavleeva

Auto-generated profile, based on publicly available information

Elena E. Pavleeva

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
OOO. D. Ostroumova
O. D. Ostroumova
AKA. I. Kochetkov
A. I. Kochetkov
EPE. E. Pavleeva
E. E. Pavleeva
EKE. V. Kravchenko
E. V. Kravchenko
Drug-induced neutropenia and agranulocytosis are serious and potentially life-threatening complications of pharmacotherapy. The aim of the review was to systematise and analyse scientific literature on the prevalence, risk factors, pathogenesis, clinical picture, methods of prevention and treatment of drug-induced neutropenia and agranulocytosis, and medicinal products that most often lead to their development. The analysis revealed that one of the major reasons of drug-induced neutropenia and agranulocytosis is the use of cytotoxic drugs (alkylating agents, antimetabolites, taxanes), non-steroidal anti-inflammatory drugs, antibiotics, antiplatelet, antithyroid, antirheumatic, antiarrhythmic, and antipsychotic drugs. The incidence of drug-induced neutropenia and agranulocytosis is generally low—from 3 to 16 cases per 1 million patients annually. The main risk factors for the development of these conditions include old age, female sex, history of chemotherapy or radiation therapy, malnutrition, and comorbidities. The symptoms in patients with neutropenia and agranulocytosis regardless of etiology can include fever, chills, apathy, myalgia, weakness, pharyngitis, gingivitis, sinusitis, stomatitis, bronchitis, and sepsis. There are no practical methods for early diagnosis or prevention of drug-induced neutropenia and agranulocytosis. Successful management of these conditions relies on timely identification and immediate withdrawal of the potential causative drug. Prevention of chemotherapy-associated neutropenia may consist in reducing the dose of the chemotherapeutic agent. Practicing physicians should be aware of the risk of drug-induced neutropenia and agranulocytosis. It is important to raise awareness among healthcare professionals of the methods of diagnosis and prevention of these conditions, as well as specific aspects of managing patients with these conditions.

11 April 2021 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
OOO. D. Ostroumova
O. D. Ostroumova
APA. P. Pereverzev
A. P. Pereverzev
EPE. E. Pavleeva
E. E. Pavleeva
РРР. Р. Романовский
Р. Р. Романовский
Drug-induced liver injury (DILI) is a fairly frequent adverse drug reaction, which accounts for about half (40–50 %) of cases of acute liver damage. The cholestatic variant of DILI is characterized by an increase in the activity of alkaline phosphatase (ALP) above the two upper limits of the norm (ULN) or the ratio of alanine aminotransferase (ALT) / ALP ≤ 2 in chronic course. A common cause of the cholestatic variant of DILI is a use of drugs for the treatment of infectious diseases, such as beta-lactam antibiotics, Aminoglycosides, Amphenicol, Lincosamides, macrolides, fluoroquinolones, antituberculosis drugs, etc. This problem has acquired particular urgency during the COVID-19 pandemic. The widespread use of azithromycin, hydroxychloroquine, interferons, lopinavir, and other drugs for the treatment of COVID-19 also contributed to an increase in the incidence of DILI. In accordance with clinical guidelines in case of suspicion of a drug-induced liver damage, one should stop use of suspected drug and, if necessary, prescribe hepatoprotectors, for example, ursodeoxycholic acid (UDCA). The effectiveness of the use of UDCA in patients with DILI, including those caused by the intake of antibacterial drugs, has been confirmed by randomized placebo-controlled clinical trials. The effectiveness of UDCA -drug Ursosan®has been confirmed in real life clinical practice. This drug can be used for long-term (up to several months), or lifelong treatment with hepatotoxic drugs like antituberculosis and antirheumatic drugs. The daily dose of Ursosan®is 12–15 mg/kg, if necessary – 20 mg / kg (with a weight of a patient about 75–100 kg, daily dose will be equal to two tablets of Ursosan Forte®, 500 mg).

24 September 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ОOО. D. Ostroumova
О. D. Ostroumova
AKA. I. Kochetkov
A. I. Kochetkov
MLM. V. Lopukhina
M. V. Lopukhina
EPE. Е. Pavleeva
E. Е. Pavleeva
The review is focused on clinical significance of the left ventricle hypertrophy (LVH) — presentation of heart lesion as a target organ for systemic hypertension (SH). Various LVH development mechanisms are presented, and special attention is paid to sympathic nervous system and β-adrenoreceptors in pathogenesis. Fundamental methods of diagnostics are described for LVH, in comparison. The pathology is classified from the perspective of recent guidelines on echocardiographic diagnostics. Epidemiology provided. Taken current evidence, the prognostic role of LVH is described as a factor increasing the risk of fatal and non-fatal cardiovascular, cerebrovascular and renal complications in SH patients. Trials data presented that points on LVH regression with highly selective β1-blocker bisoprolol treatment. Pathophysiology of LVH regression is discussed for β1-blocker treatment.

1 April 2024 in Russian Journal of Evidence-Based Gastroenterology
Verified
Journal Article
Closed access
AKA.N. Kazyulin
A.N. Kazyulin
AGA.YU. Goncharenko
A.YU. Goncharenko
EPE.E. Pavleeva
E.E. Pavleeva
ILI.YU. Lyubozhnova
I.YU. Lyubozhnova
IKI.E. Kalyagin
I.E. Kalyagin
Objective. To analyze existing literature to identify similarities and differences in the epidemiological, clinical, diagnostic, and therapeutic aspects of irritable bowel syndrome (IBS) and conditions with IBS-like symptoms. Key points. The review explores the similarities and differences among various conditions, including celiac disease, non-celiac gluten sensitivity, wheat allergy, increased non-gluten alpha-amylase/trypsin inhibitors, nickel allergic contact mucositis, consumption of high FODMAP foods, lactose intolerance, small intestinal bacterial overgrowth syndrome, inflammatory bowel diseases in remission, chronic pancreatitis, and gynecological disorders. Analysis of clinical studies has led to several hypotheses indicating that conditions with IBS-like symptoms share common features and pathogenesis with conditions with IBS-like symptoms, such as increased intestinal permeability, mucosal mediator release, upregulation of proinflammatory cytokines, neurogenic gut dysfunction, and disruption of the brain-gut axis. Conclusion. It is currently postulated that using new diagnostic tools is advisable for identifying conditions with IBS-like symptoms in patients. The common pathogenesis suggests the potential use of a single therapeutic approach for patients with IBS and those with similar symptoms.

2 October 2021 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
APA. P. Pereverzev
A. P. Pereverzev
OOO. D. Ostroumova
O. D. Ostroumova
OGO. V. Golovina
O. V. Golovina
AFA. V. Filippova
A. V. Filippova
ЕPЕ. Е. Pavleeva
Е. Е. Pavleeva
He liver is one of the organs most often affected by medication (MP) intake. Drug-induced liver damage with cholestasis (LIPCH), on the one hand, rarely leads to death in comparison with the hepatocellular type, but, on the other hand, is more often characterized by a long, in some cases chronic course. This type of liver damage is characterized by an increase in the activity of alkaline phosphatase (ALP) > 2 upper limits of normal (ULN) or the ratio of alanine aminotransferase (ALT) / ALP < 2 in chronic course. Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most readily available (including over-the-counter) and widely used drugs in clinical practice and are often the cause of LIPCH. This article summarizes the available data at the time of preparation of the article on the prevalence, mechanisms of development and features of LIPPH while taking NSAIDs. A separate section is highlighted on the features of the management of such patients. In particular, in accordance with both domestic and foreign clinical guidelines for the drug genesis of liver damage, it is recommended to stop taking the inducer drug and prescribe ursodeoxycholic acid (UDCA). The efficacy of UDCA in patients with LIPCH, including those associated with the use of NSAIDs, has been confirmed by the results of a large number of randomized placebo-controlled clinical trials. Among the UDCA preparations on the market of the Russian Federation, one cannot fail to pay attention to Exho® (CJSC «Canonpharma Production»), which is bioequivalent to the reference drug, is produced in compliance with GMP standards on a high-tech production base, which ensures its quality, and an affordable price and a large the choice of dosage forms makes it possible to successfully use this drug, including in special categories of patients, for example, elderly patients and/or those suffering from dysphagia.

19 September 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EBE. V. Borisova
E. V. Borisova
OOO. D. Ostroumova
O. D. Ostroumova
APA. P. Pereverzev
A. P. Pereverzev
EPE. E. Pavleeva
E. E. Pavleeva
Cardiovascular diseases (CVD) are the leading cause of death among adults worldwide, including in the Russian Federation. At the same time, the leading position in the structure of causes of death from CVD is occupied by coronary heart disease (CHD) (16% of the total number of deaths in the world per year). The new clinical guidelines of the Ministry of Health of the Russian Federation for the management of patients with stable coronary heart disease in 2020 identify two main goals of conservative therapy – the elimination of symptoms of the disease and the prevention of cardiovascular complications (CVD). In this connection, when choosing antianginal therapy in patients with stable angina, it is necessary to consider the possibility of using combinations of both first-line and second-line drugs in order to really improve the effectiveness of treatment and achieve the goals set. It is advisable and justified to use more widely 2-line drugs, in particular trimetazidine, at any stage of therapy to enhance the antianginal effectiveness of b-blockers, calcium antagonists and prolonged-acting nitrates, especially in patients with hemodynamic features (arterial hypotension, rhythm and conduction disorders), which is demonstrated in the given clinical example. The effective addition of tremetazidine to the arsenal of traditional antianginal drugs is legislated in practice and is reflected in the new clinical recommendations of the Ministry of Health of the Russian Federation in 2020. The accumulated experience of using trimetazidine allows a pathogenetically sound approach to the treatment of stable CHD, restoring the balance between the need and delivery of oxygen to the heart muscle, and the safety profile expands the possibilities of use in patients with comorbid pathology.